Compare AXIL & IMMP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AXIL | IMMP |
|---|---|---|
| Founded | 2015 | 1987 |
| Country | United States | Australia |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.5M | 42.4M |
| IPO Year | 2017 | 2012 |
| Metric | AXIL | IMMP |
|---|---|---|
| Price | $6.27 | $0.26 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $5.50 |
| AVG Volume (30 Days) | 18.2K | ★ 324.8K |
| Earning Date | 04-08-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 230.00 | N/A |
| EPS | ★ 0.33 | N/A |
| Revenue | ★ $30,847,570.00 | N/A |
| Revenue This Year | N/A | $445.09 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $18.76 | ★ N/A |
| Revenue Growth | ★ 17.48 | N/A |
| 52 Week Low | $4.28 | $0.26 |
| 52 Week High | $9.86 | $3.53 |
| Indicator | AXIL | IMMP |
|---|---|---|
| Relative Strength Index (RSI) | 52.43 | 29.26 |
| Support Level | $6.02 | N/A |
| Resistance Level | $7.39 | $0.40 |
| Average True Range (ATR) | 0.24 | 0.02 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 78.65 | 7.86 |
AXIL Brands Inc is a company which is is a manufacturer and marketer of premium hearing enhancement and protection products, including ear plugs, earmuffs, and ear buds, and outdoor speakers, under the AXIL brand. AXIL delivers top hearing enhancement, protection, & audio devices. From ultra comfortable fitting processes, to stereo quality sound performance, to reliable & durable engineering. The company operates two operating segments: hearing enhancement and protection, and hair and skin care.
Immutep Ltd is a clinical-stage biotechnology company developing novel Lymphocyte Activation Gene-3 (LAG-3) related immunotherapies for cancer and autoimmune disease. It has a diversified product portfolio that harnesses LAG-3's ability to stimulate the body's immune response to fight cancer or suppress the immune system to treat autoimmune disease. The company is focused on advancing its product candidate, eftilagimod alfa (efti), through its registrational Phase three clinical trial towards marketing approval in first-line non-small cell lung cancer (1L NSCLC). The other product candidates in its portfolio include TACTI-003, AIPAC-003, TACTI-002, INSIGHT-005, and others, being developed as potential therapies for various cancers and autoimmune diseases.